Fragen? Antworten! Siehe auch: Alternativlos
Teva had argued that the details provided in Pfizer's original patent application (number 2,163,446, granted in 1998 and set to expire in 2014) was invalid because in it, Pfizer listed several different chemical compounds without ever specifying which one was the actual active ingredient - sildenafil.Damit haben sie die Grundidee von Patenten verletzt, nämlich dass man offenlegt.